MedPage Today (5/6, George) reports a study found that “fremanezumab (Ajovy) reduced depression symptoms and monthly migraine attacks in people with episodic or chronic migraine and major depressive disorder.” Researchers observed that the “mean change from baseline in monthly migraine days during a 12-week double-blind period was -5.1 days with fremanezumab and -2.9 days with placebo.” In addition, the “mean changes from baseline in Hamilton Depression Rating Scale-17 Items (HAM-D 17) scores at 8 weeks were -6.0 points for fremanezumab and -4.6 points for placebo. The mean difference in HAM-D 17 scores at week 8 was -1.4 points.” Researchers concluded, “The treatment results appear comparable to those in non-depressed patients with migraine, which is reassuring.” The study was published in JAMA . (SOURCE: APA Headlines)